Hematology/Oncology

Top Story

Duvelisib extends PFS in relapsed or refractory chronic lymphocytic leukemia

December 11, 2017

ATLANTA — Duvelisib significantly prolonged PFS compared with ofatumumab among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to results of the DUO trial presented at ASH Annual Meeting and Exposition.

Researchers observed PFS advantages in all analyzed subgroups, including patients with 17p deletion, a genotype often associated with poor prognosis.

Meeting News

Circulating tumor DNA reliably measures lymphoma disease burden

December 11, 2017
ATLANTA — Circulating tumor DNA appeared to be a reliable biomarker in aggressive lymphomas and could be used to refine clinical estimates of disease burden among…
Meeting NewsPerspective

Tisagenlecleucel induces durable responses in relapsed, refractory DLBCL

December 10, 2017
ATLANTA — Treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel led to durable responses among highly pretreated patients with relapsed and…

Immunosuppressive therapy leads to transfusion independence for nearly 40% of patients with myelodysplastic syndrome

December 10, 2017
ATLANTA — Immunosuppressive therapy helped nearly 40% of patients with myelodysplastic syndrome achieve transfusion independence, according to study results…
Meeting NewsPerspective

Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphoma

December 10, 2017
ATLANTA — More than half of patients with refractory, aggressive non-Hodgkin lymphoma remained alive at least 1 year after receiving a single infusion of anti-CD19…
More Headlines »
CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »
Video
Meeting News

VIDEO: Letermovir CMV prophylaxis offers survival benefit in hematopoietic cell transplant patients

October 14, 2017
More »
Resource Centers

CME

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement